Quantcast

Latest Amides Stories

2014-08-19 08:29:50

VAL-083 Phase I/II VAL-083 clinical trial advances to 50mg/m(2) cohort VANCOUVER, British Columbia and MENLO PARK, Calif., Aug. 19, 2014 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (OTCQB: DMPI) ("DelMar" "the company") announced today a protocol amendment to allow for expanded dosing in its VAL-083 clinical trial had been filed with the U.S. Food and Drug Administration (FDA) and that a new cohort of a new 50mg/m(2) has been opened at three clinical trial sites in the United...

2014-08-19 08:29:39

DUBLIN, Aug. 19, 2014 /PRNewswire/ -- Actavis plc (NYSE: ACT) today confirmed positive topline results from RECLAIM-1 and -2, pivotal Phase III studies evaluating the potential for the investigational antibiotic, ceftazidime-avibactam as a treatment for adult hospitalized patients with complicated intra-abdominal infections. Logo - http://photos.prnewswire.com/prnh/20130124/NY47381LOGO Ceftazidime-avibactam consists of a cephalosporin (ceftazidime), an established treatment for...

2014-08-17 23:00:12

All Aspects Of Litigation Surrounding The Federal Pradaxa Lawsuits Alleging Boehringer Ingelheim's Blood Thinner Caused Serious Internal Bleeding Have Been Suspended Until Completion Of A Settlement Agreement Reports Wright & Schulte LLC Columbus, OH (PRWEB) August 18, 2014 The attorneys at Wright & Schulte LLC note all matters within the Pradaxa lawsuit litigation were recently placed on hold while plaintiffs’ attorneys and Pradaxa manufacturer Boehringer Ingelheim...

2014-08-13 23:11:30

Thousands of Pradaxa Lawsuits Currently Pending in U.S. Courts Accuse Boehringer Ingelheim of Failing to Provide Adequate Warnings Regarding Medication’s Alleged Bleeding Side Effects New York NY (PRWEB) August 13, 2014 Pradaxa Lawsuit News: As Pradaxa lawsuits continue to move forward in U.S. courts, several new reports published in the British Medical Journal are raising new questions about the data used to garner regulatory approval of the blood thinner. Among other things, the...

2014-08-05 23:11:11

The DrugNews Center is the web’s largest source for prescription drug warnings, research and legal news. Visit http://www.DrugNews.net today. New York, NY (PRWEB) August 05, 2014 The drug safety advocates at DrugNews.net are alerting patients who have taken the anticoagulant Xarelto of new information on the site. A recent report advises that complaints of internal bleeding linked to Xarelto have now surpassed those of competitors*. DrugNews is a free resource providing the latest...

2014-07-28 23:01:24

Advanced Recovery, Absorption & Immune System Support* New York, NY (PRWEB) July 28, 2014 Glutamine is the most abundant single amino acid in the body and it’s considered to be conditionally essential during times when the body undergoes large amounts of stress and is an advanced recovery & Immune System Support. Having a heavy work out regimen, burns all the glutamine your body produces, supplementing with additional glutamine may be advantageous. Glutamine supplementation may...

2014-07-27 23:02:21

Reports of Xarelto Bleeding Mounts As Doctors Are Prescribing Xarelto Over Pradaxa and Seeing a Rise In Adverse Events While Xarelto Lawsuits Begin to be Filed Reports Wright & Schulte LLC Columbus, OH (PRWEB) July 27, 2014 The Institute of Safe Medication Practices (ISMP) Found that the number of serious adverse events such as Xarelto bleeding side-effects reported after the use of the Xarelto blood thinner has now out numbered the complaints filed for its competitor Pradaxa, notes...

2014-07-25 04:21:37

WHIPPANY, N.J. and SOUTH SAN FRANCISCO, Calif., July 25, 2014 /PRNewswire/ -- Bayer HealthCare and Onyx Pharmaceuticals Inc., an Amgen subsidiary (NASDAQ: AMGN), today announced that an investigational Phase 3 trial of NEXAVAR(®) (sorafenib) tablets in patients with advanced breast cancer did not meet its primary endpoint of improving progression-free survival (PFS). The study, called RESILIENCE, evaluated the efficacy and safety of sorafenib in combination with capecitabine, an...

2014-07-23 16:26:55

British Medical Journal publishes biased article regarding PRADAXA RIDGEFIELD, Conn., July 23, 2014 /PRNewswire/ -- Boehringer Ingelheim (BI) wants to set the record straight following misleading statements that the British Medical Journal (BMJ) published today regarding Pradaxa® (dabigatran etexilate mesylate). We are concerned that this publication may alarm patients and prompt them to stop taking PRADAXA, thereby increasing their risk of stroke. To be clear, many of the allegations made...

2014-07-14 08:26:37

SAN ANTONIO, July 14, 2014 /PRNewswire/ -- GenSpera, Inc. (OTCQB: GNSZ), a leader in developing prodrug therapeutics for the treatment of cancer, announces that Kareg Corporation's Director of Research, Sheldon S. Traube, has issued the following research report on the company. Sheldon S. Traube, Director of Research, Kareg Corporation, Initiating Coverage with a Speculative Buy Recommendation Read the full report: http://www.genspera.com/press/140711_Genspera_research_report_July2014.pdf...


Word of the Day
omadhaun
  • A fool; a simpleton: a term of abuse common in Ireland and to a less extent in the Gaelic-speaking parts of Scotland.
This word is partly Irish in origin.